

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

1. (currently amended) A method for treating a patient diagnosed with ~~an ophthalmic disease~~open-angle glaucoma caused by premature stop mutations in a gene, wherein the method comprises administering to such patient a composition comprising an aminoglycoside antibiotic compound.
2. (cancelled)
3. (currently amended) The method of Claim 21 wherein the patient is diagnosed with a stop mutation in a gene selected from the group consisting of GLC1A and CYP1B1.
4. A method for treating a patient diagnosed with ~~an ophthalmic disease~~open-angle glaucoma caused by premature stop mutations in a gene, wherein the method comprises locally administering to the eye of such patient a composition comprising an aminoglycoside antibiotic compound.
5. (cancelled)
6. (currently amended) The method of Claim 5 4 wherein the patient is diagnosed with a stop mutation in a gene selected from the group consisting of GLC1A and CYP1B1.
7. (currently amended) The method of Claim 5 4 wherein the aminoglycoside antibiotic is selected from the group consisting of gentamicin; tobramycin; metilmicin; amilcacin; kanamycins A and B; streptomycin; netilmicin; and neomycin.
8. (currently amended) The method of Claim 5 4 wherein the composition is topically administered as an eye drop.
9. The method of Claim 8 wherein the aminoglycoside antibiotic compound is present in the composition in an amount of 1% (w/w) or less.

10. The method of Claim 9 wherein the aminoglycoside antibiotic compound is present in the composition in an amount of 0.2 – 0.4% (w/w).